Abstract
Single doses of MAALOX TC and ranitidine were administered separately with 1,400 mg of fosamprenavir (FPV). MAALOX TC decreased the area under the concentration-time curve from 0 to 24 h (AUC(0-24)) for plasma amprenavir (APV) by 18% and the maximum concentration of drug in serum (C(max)) by 35%; the plasma APV concentration at 12 h (C(12)) increased by 14%. Ranitidine at 300 mg decreased the AUC(0-24) for plasma APV by 30% and C(max) by 51%; C(12) was unchanged. FPV may be coadministered with antacids without concern and without separation in dosing; however, caution is recommended when FPV is coadministered with histamine(2)- receptor antagonists or proton pump inhibitors.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Aluminum Hydroxide / administration & dosage
-
Aluminum Hydroxide / pharmacology*
-
Antacids / administration & dosage
-
Antacids / pharmacology*
-
Anti-Ulcer Agents / administration & dosage
-
Anti-Ulcer Agents / pharmacology*
-
Area Under Curve
-
Carbamates
-
Drug Administration Schedule
-
Drug Combinations
-
Drug Interactions
-
Furans
-
HIV Protease Inhibitors / administration & dosage
-
HIV Protease Inhibitors / pharmacokinetics*
-
Humans
-
Magnesium Hydroxide / administration & dosage
-
Magnesium Hydroxide / pharmacology*
-
Organophosphates / administration & dosage
-
Organophosphates / pharmacokinetics*
-
Ranitidine / administration & dosage
-
Ranitidine / pharmacology*
-
Sulfonamides / administration & dosage
-
Sulfonamides / blood
-
Sulfonamides / pharmacokinetics*
Substances
-
Antacids
-
Anti-Ulcer Agents
-
Carbamates
-
Drug Combinations
-
Furans
-
HIV Protease Inhibitors
-
Organophosphates
-
Sulfonamides
-
aluminum hydroxide, magnesium hydroxide, drug combination
-
Aluminum Hydroxide
-
amprenavir
-
Ranitidine
-
Magnesium Hydroxide
-
fosamprenavir